Biohaven Ltd. (BHVN) stock
BHVNNYSEPharmaceutical PreparationsFiscal year ends December 31
$13.24−0.56 (-4.06%)
Close on Nov 17, 2026Market cap $2.00BP/E –Yield –
Biohaven ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Biohaven's ebitda for the twelve months ending Sep 30, 2026 was -$515.06M. For fiscal 2025 it was -$735.46M. The highest annual figure on record is -$114.43M in fiscal 2020.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$735.46M | – |
| FY2024 | Dec 31, 2024 | -$877.26M | – |
| FY2023 | Dec 31, 2023 | -$429.14M | – |
| FY2022 | Dec 31, 2022 | -$566.55M | – |
| FY2021 | Dec 31, 2021 | -$217.51M | – |
| FY2020 | Dec 31, 2020 | -$114.43M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$124.20M | – |
| Q2 FY2026 | Jun 30, 2026 | -$122.64M | – |
| Q1 FY2026 | Mar 31, 2026 | -$128.06M | – |
| Q4 FY2025 | Dec 31, 2025 | -$140.16M | – |
| Q3 FY2025 | Sep 30, 2025 | -$166.26M | – |
| Q2 FY2025 | Jun 30, 2025 | -$209.72M | – |
| Q1 FY2025 | Mar 31, 2025 | -$219.32M | – |
| Q4 FY2024 | Dec 31, 2024 | -$187.47M | – |
| Q3 FY2024 | Sep 30, 2024 | -$176.17M | – |
| Q2 FY2024 | Jun 30, 2024 | -$331.82M | – |
| Q1 FY2024 | Mar 31, 2024 | -$181.79M | – |
| Q4 FY2023 | Dec 31, 2023 | -$151.82M | – |
| Q3 FY2023 | Sep 30, 2023 | -$109.01M | – |
| Q2 FY2023 | Jun 30, 2023 | -$92.18M | – |
| Q1 FY2023 | Mar 31, 2023 | -$76.13M | – |
| Q4 FY2022 | Dec 31, 2022 | -$213.07M | – |
| Q3 FY2022 | Sep 30, 2022 | -$67.26M | – |
| Q2 FY2022 | Jun 30, 2022 | -$196.70M | – |
| Q1 FY2022 | Mar 31, 2022 | -$89.52M | – |
| Q4 FY2021 | Dec 31, 2021 | -$50.20M | – |
See a number that looks wrong?